Ebola, DRC reports 4,945 confirmed cases and ECDC confirms "very low" risk in Europe

The International Health Regulations emergency committee on the Bundibugyo ebolavirus outbreak is meeting today in Geneva for the second time, as reported in the morning edition. In the following hours, the two elements that this meeting will need to assess became readable: the most recent figures on the outbreak and the risk assessment for unaffected countries.

On August 16 the Democratic Republic of the Congo reported a total of 4,945 confirmed cases and 2,325 related deaths, with 730 patients in isolation (ECDC). The World Health Organization’s count, updated to August 12, indicated 4,665 confirmed cases and 2,184 deaths, with a crude case fatality rate of 46.8% (WHO). The two sets of figures are not contradictory: they differ in update date and validation chain, and the first is the Congolese Ministry of Health’s figure as picked up by the European agency.

The term “crude fatality rate” requires a clarification, since it is the figure cited most often and understood least: 46.8% is the ratio between deaths recorded and cases confirmed as of a given date, not the probability of outcome for a person contracting the infection today. In an ongoing outbreak the denominator contains patients whose outcome is not yet known, which makes the value a moving one.

The European assessment

The ECDC considers the probability of Bundibugyo ebolavirus infection for people living in the European Union and the European Economic Area to be “very low.” In the same assessment the agency notes that significant gaps remain in the surveillance and epidemiology of the outbreak: this is a warning about the quality of the data on which the assessment itself is based, and the two elements should be read together.

In 2026 two imported cases were recorded in Europe. On July 10 the United States Centers for Disease Control and Prevention reported that a US citizen employed by a humanitarian organization in the DRC had tested positive for Bundibugyo ebolavirus, and was evacuated to Germany on July 13; on June 24 the French Ministry of Health had reported a further imported case in France (CDC). The CDC itself states that no case linked to this outbreak has been confirmed in the United States and that the risk to the population remains low.

These two episodes are the most useful piece of information for understanding what “very low risk” means: not the absence of cases, but their management within dedicated evacuation and isolation pathways.

The state of vaccines

Bundibugyo ebolavirus is a species for which no approved vaccines or specific treatments exist; the WHO states that studies are underway on candidates described as promising (WHO).

On this point the limitations must be stated in full, because they consist almost entirely of missing information. The institutional material available does not indicate the trial phase of the candidates, does not report the size or composition of the enrolled samples, does not describe the method used — whether there is a control group, whether assignment is randomized, whether the assessment is blinded — and contains no results published in a peer-reviewed journal. No conflict of interest is disclosed, for the reason that it is not even disclosed which parties are conducting or funding the research.

It follows that “promising” is a WHO qualification of the status of a research pathway, not a measure of efficacy: no data available makes it possible to establish a causal relationship between the administration of one of these candidates and a clinical outcome, and an ongoing study is not an available therapy. Beyond this we add nothing.

The organization also continues to recommend that no restrictions be applied to travel or trade with affected countries: this is a WHO recommendation to states, reported here as such.

The outbreak in the DRC and Uganda was declared a public health emergency of international concern on May 17, 2026 by the WHO Director-General, and ahead of today’s meeting the organization prepared an updated rapid risk assessment. The ECDC’s next epidemiological update is expected on August 18, on a weekly basis in the communicable disease threats report: this is where the figures in this piece will be reviewed.